Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

New Thai Health Minister Promises To Break Drug Patents

This article was originally published in PharmAsia News

Executive Summary

Thailand's new health minister has made it clear he intends to use the country's compulsory licensing law to ensure Thais have access to key drugs at lower prices. Public Health Minister Chaovarat Chanweerakul's stance on the issue had been doubted by non-government organizations that feared he would side with drug makers and not use the CL policy. But at Chaovarat's arrival on the job, he promised he would break patents on life-saving drugs when necessary. (Click here for more

You may also be interested in...



Sanofi Asks Thailand To Review Compulsory Licensing Policy

Sanofi-Aventis sent a request to the previous Thai Minister of Commerce Mingkwan Sangsuwan to review the process of compulsory licensing on patented drugs, Graham Almond, Sanofi-Aventis Thailand general manager told PharmAsia News.

Executives On The Move: Kiadis, Oncologie and Atossa Therapeutics Fill Senior Positions

New chief medical officers take up positions at Abeona Therapeutics, Akcea Therapeutics and Oncologie, while there are new CFOs at Affimed, NGM Biopharmaceuticals, Phathom Pharmaceuticals, Oncologie and Syndax Pharmaceuticals.

Infirst Launches GSL Version Of Flarin Lipid Ibuprofen In UK

Consumers in the UK can now self-select a version of Infirst's lipid-driven ibuprofen Flarin brand. 

UsernamePublicRestriction

Register

LL1126271

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel